JPS6461421A - Composition based on phosphatidyl choline and medicinal use - Google Patents

Composition based on phosphatidyl choline and medicinal use

Info

Publication number
JPS6461421A
JPS6461421A JP63166650A JP16665088A JPS6461421A JP S6461421 A JPS6461421 A JP S6461421A JP 63166650 A JP63166650 A JP 63166650A JP 16665088 A JP16665088 A JP 16665088A JP S6461421 A JPS6461421 A JP S6461421A
Authority
JP
Japan
Prior art keywords
fatty acid
phosphatidyl choline
salt solution
unsaturated fatty
dispersing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63166650A
Other languages
English (en)
Japanese (ja)
Inventor
Ratsususoon Koore
Bengumaruku Suteiigu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS6461421A publication Critical patent/JPS6461421A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP63166650A 1987-07-06 1988-07-04 Composition based on phosphatidyl choline and medicinal use Pending JPS6461421A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8702784A SE457933B (sv) 1987-07-06 1987-07-06 Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion

Publications (1)

Publication Number Publication Date
JPS6461421A true JPS6461421A (en) 1989-03-08

Family

ID=20369073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63166650A Pending JPS6461421A (en) 1987-07-06 1988-07-04 Composition based on phosphatidyl choline and medicinal use

Country Status (3)

Country Link
EP (1) EP0299937A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS6461421A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE457933B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003506397A (ja) * 1999-08-06 2003-02-18 マックス−デルブルック−セントルム フュア モレキュラー メディツィン 埋め込み可能な有効成分デポ剤
JP2005047929A (ja) * 1998-05-13 2005-02-24 Ml Lab Plc 外科手術上の癒着を阻止するためのデキストリンを含有する組成物
WO2008084864A1 (ja) * 2007-01-11 2008-07-17 Nisshin Pharma Inc. カプサイシン受容体活性化剤及びそれを噴霧する装置
JP2013542917A (ja) * 2010-08-13 2013-11-28 コンパニ・ジェルベ・ダノン 胃上部領域のための製品

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4005711C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1990-02-23 1991-06-13 A. Nattermann & Cie Gmbh, 5000 Koeln, De
FR2670365B1 (fr) * 1990-12-18 1993-12-24 Eurial Boisson lactee et procede pour sa preparation.
FR2714621B1 (fr) * 1994-01-06 1996-02-23 Centre Nat Rech Scient Procédé de préparation de liposomes sans utilisation de solvant organique.
AU702030B2 (en) * 1995-10-12 1999-02-11 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
AU2003266884A1 (en) * 2002-09-16 2004-04-30 Vasogen Ireland Limited Accelerating recovery from trauma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
DE3028074C2 (de) * 1980-07-22 1983-12-08 Kurt Kampffmeyer Mühlenvereinigung KG, 2000 Hamburg Verfahren zur Herstellung eines lecithinhaltigen Produktes
DE3470277D1 (en) * 1984-01-11 1988-05-11 Von Mletzko Armin Dietetic composition
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005047929A (ja) * 1998-05-13 2005-02-24 Ml Lab Plc 外科手術上の癒着を阻止するためのデキストリンを含有する組成物
JP2003506397A (ja) * 1999-08-06 2003-02-18 マックス−デルブルック−セントルム フュア モレキュラー メディツィン 埋め込み可能な有効成分デポ剤
WO2008084864A1 (ja) * 2007-01-11 2008-07-17 Nisshin Pharma Inc. カプサイシン受容体活性化剤及びそれを噴霧する装置
JP2013542917A (ja) * 2010-08-13 2013-11-28 コンパニ・ジェルベ・ダノン 胃上部領域のための製品

Also Published As

Publication number Publication date
EP0299937A1 (en) 1989-01-18
SE457933B (sv) 1989-02-13
SE8702784D0 (sv) 1987-07-06
SE8702784L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-01-07

Similar Documents

Publication Publication Date Title
Nakashima et al. Effect of a high linoleate and a high alpha-linolenate diet on general behavior and drug sensitivity in mice.
CA2281706C (en) Methods and compositions for reducing the incidence of necrotizing enterocolitis
US11065267B2 (en) Lysophosphatidylcholine compositions
JPS6461421A (en) Composition based on phosphatidyl choline and medicinal use
GB2084172A (en) Lipid compositions useful in dietetics
EP0180786A1 (en) Pharmaceutical or dietetic composition having a high antithrombotic and antiarteriosclerotic activity
UA76108C2 (en) Use of therapeutic combination of fatty acids
KR930012039A (ko) 초음파 화상형성용 콘트라스트제
DK68080A (da) Anvendelse af fuldstaendigt acetylerede monoglycerider til saenkning af forhoejede cholesterinspejl og eller neutralfedtspejl i menneskeblod
JPS6413021A (en) Lithium salt-containing pharmacological composition
DE69512929T2 (de) Salze von aminoalkoholen und diese enthaltende pharmazeutische zusammensetzungen
EP0734723A1 (en) Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
HUP0101248A2 (hu) Gyomor- és/vagy nyombél-adhezív gyógyászati készítmények
Krawitt et al. The role of intestinal transport proteins in cortisone-mediated suppression of Ca2+ absorption
Manitius et al. Some observations on the influence of a magnesium-deficient diet on rats, with special reference to renal concentrating ability
ATE227304T1 (de) Tetraetherlipide und diese enthaltende liposomen sowie deren verwendung
JPS60105471A (ja) 健康食品卵の生産方法
PT682879E (pt) Produto alimentar dietetico com acidos gordos de cadeia media e sua utilizacao
NO20002045D0 (no) Fremgangsmõte for øking av konsentrasjonen av konjugert linolsyre i melk og/eller vevfett av en drøvtygger
Tichelaar et al. The effect of dietary iron deficiency on the fatty acid composition of plasma and erythrocyte membrane phospholipids in the rat
ES538982A0 (es) Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas.
Shoshkes et al. Fat Emulsions for Oral Nutrition. II. Failure of Phosphatide, Tween 80, or Choline to Influence Fat Absorption.
Caskey et al. Relative effectiveness of ingested and injected manganese in preventing perosis.
IL86638A0 (en) (2-cyano-2-oximinoacetyl)-amino acid derivatives,their preparation and their use as pesticides
DE2640707A1 (de) Gewinnung von im darm resorbierbaren protein- und peptidloesungen